- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Bristol Myers Squibb faces revenue compression due to European exclusivity loss and US pricing limits after product required FDA approval.
1 report, 1 independent
Updated May 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol Myers Squibb faces revenue compression due to European exclusivity loss and US pricing limits after product required FDA approval.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The market responded negatively to management concerns regarding Bristol-Myers Squibb's business challenges.Sub-event
BMS faces revenue compression from European exclusivity loss and US pricing limits.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- Market competition observed in the large-cap healthcare sector involving Bristol-Myers Squibb and Orion OYJ.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA approval clears the path for drug market entry, driving future regulatory focus for major pharmaceutical companies.
- CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.